Asia-Pacific infectious disease diagnostics market trends In Asia-Pacific (APAC), many countries continue to build up… In-vitro diagnostics | Infectious Diseases Testing Monitor | Uncategorised | Asia | Infectious Diseases Testing Monitor | IVD Gateway
Medtech 2022/2023: seeking sustainable growth Global healthcare spending growth in 2022 has slowed despite… In-vitro diagnostics | Surgical device | Global | IVD Gateway | Surgical Gateway
Supporting the global launch of a clinical chemistry assay One of the largest IVD multinational companies plans to… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Global | Centralised Diagnostics (CEDx) | IVD Gateway
How Vision 2030 is driving growth in Saudi Arabia’s IVD market The incidence of cardiovascular diseases (CVD) in… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx)
Middle East IVD market to recover to pre-pandemic growth rates from 2024 The Middle East IVD market has mostly recovered to… Centralised Diagnostics (CEDx) | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Middle East & Africa | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT)
Cardiac biomarker testing market outlook in Latin America The incidence of cardiovascular diseases (CVD) in… In-vitro diagnostics | Point-of-care testing (POCT) | Americas | IVD Gateway | Point-of-care testing (POCT)
The future of point-of-care cardiac biomarker testing With longer life expectancies in APAC, there is an… In-vitro diagnostics | Point-of-care testing (POCT) | Global | IVD Gateway | Point-of-care testing (POCT) | The Gateway
Cardiac biomarker testing market outlook in Asia-Pacific The incidence of cardiovascular diseases (CVD) in… In-vitro diagnostics | Point-of-care testing (POCT) | Asia | IVD Gateway | Point-of-care testing (POCT)
Cancer biomarker testing to grow in Asia The cancer burden in Asia is increasing, with new cancer… Cancer diagnostics | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | IVD Gateway | Molecular Diagnostics (MDx) | Size and Share Plus | The Gateway
Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge The impact of China’s latest covid-19 surge heads the… Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)
Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels Asia-Pacific (APAC) IVD markets have grown and exceeded… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)
Most common cancer biomarkers for Europe NGS testing: RAS, BRAF, EGFR Most-commonly tested cancer biomarkers using NGS in Europe… Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Europe | IVD Gateway | LabPRO Plus | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx)